摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-t-BuC6H4PH2 | 1237893-83-2

中文名称
——
中文别名
——
英文名称
2-t-BuC6H4PH2
英文别名
(2-Tert-butylphenyl)phosphane
2-t-BuC6H4PH2化学式
CAS
1237893-83-2
化学式
C10H15P
mdl
——
分子量
166.203
InChiKey
DSPVHUQMZVNQRX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    0
  • 氢给体数:
    0
  • 氢受体数:
    0

反应信息

  • 作为反应物:
    描述:
    2-t-BuC6H4PH2甲基锂三甲基氯硅烷 作用下, 以 四氢呋喃乙醚 为溶剂, 以72%的产率得到2-t-BuC6H4P(SiMe3)2
    参考文献:
    名称:
    勘误表:合成具有邻位取代芳基的功能性膦:2-RC6H4PH2 和 2-RC6H4P(SiMe3)2(R = i-Pr- 或 t-Bu)
    摘要:
    AbstractThe synthesis and characterization of 2‐i‐PrC6H4PCl2 (3), 2‐t‐BuC6H4PCl2 (4), 2‐i‐PrC6H4PH2 (5), 2‐t‐BuC6H4PH2 (6), 2‐i‐PrC6H4P(SiMe3)2 (7), and 2‐t‐BuC6H4P(SiMe3)2 (8) are described. © 2010 Wiley Periodicals, Inc. Heteroatom Chem 21:355–360, 2010; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/hc.20619*This is a revised version of the article originally published in Volume 21, Number 4 (Heteroatom Chem 21:265‐270, 2010; DOI 10.1002/hc.20606). Due to an unfortunate publisher's error, the earlier version was posted online and approved for press before the journal's production team had received the authors' proof corrections. The publisher regrets the oversight.
    DOI:
    10.1002/hc.20619
  • 作为产物:
    描述:
    1-溴-2-叔丁基苯盐酸 、 lithium aluminium tetrahydride 、 magnesium 作用下, 以 四氢呋喃乙醚二氯甲烷 为溶剂, 生成 2-t-BuC6H4PH2
    参考文献:
    名称:
    合成具有邻位取代芳基的功能性膦:2-RC6H4PH2 和 2-RC6H4P(SiMe3)2(R = 2-i-Pr- 或 2-t-Bu-)
    摘要:
    2-i-PrC6H4PCl2 (3), 2-t-BuC6H4PCl2 (4), 2-i-PrC6H4PH2 (5), 2-t-BuC6H4PH2 (6), 2-i-PrC6H4P(SiMe3)2的合成与表征(7) 和 2-t-BuC6H4P(SiMe3)2 (8) 进行了描述。© 2010 Wiley Periodicals, Inc. 杂原子化学 21:355–360, 2010; 在线发表于 Wiley InterScience (www.interscience.wiley.com)。DOI 10.1002/hc.20619*
    DOI:
    10.1002/hc.20606
点击查看最新优质反应信息

文献信息

  • N-(PHOSPHINOALKYL)-N-(THIOALKYL)AMINE DERIVATIVE, METHOD FOR PRODUCING SAME, AND METAL COMPLEX THEREOF
    申请人:TAKASAGO INTERNATIONAL CORPORATION
    公开号:US20170233418A1
    公开(公告)日:2017-08-17
    The purpose of the present invention is to provide: a ligand that is useful in a catalytic organic synthetic reaction; a method for producing said ligand; and a metal complex that is useful as a catalyst in an organic synthetic reaction. The present invention provides a compound represented by general formula (1 A ), a method for producing said compound, and a metal complex including said compound as a ligand. (In the formula, H, N, P, S, L, R 1 , R 2 , R 3 , Q 1 , and Q 2 have the meaning as defined in the Description.)
    本发明的目的是提供:在催化有机合成反应中有用的配体;制备所述配体的方法;以及在有机合成反应中作为催化剂有用的属配合物。本发明提供了由通式(1A)表示的化合物,制备所述化合物的方法,以及包括所述化合物作为配体属配合物。(在该式中,H、N、P、S、L、R1、R2、R3、Q1和Q2的含义如描述中所定义。)
  • Novel Crystalline Form
    申请人:Lindsjö Martin
    公开号:US20110224229A1
    公开(公告)日:2011-09-15
    Crystalline Forms of 6-[2-(4-cyano-phenyl)-2H-pyrazol-3-yl]-5-methyl-3-oxo-4-(3-trifluoromethyl-phenyl)-3,4-dihydro-pyrazine-2-carboxylic acid ethylamide are disclosed together with processes for preparing the Forms, pharmaceutical compositions comprising the Forms, and the use of the Forms in therapy.
    本发明公开了6-[2-(4-基苯基)-2H-吡唑-3-基]-5-甲基-3-氧代-4-(3-三甲基苯基)-3,4-二氢-吡嗪-2-羧酸乙酰胺的晶型形式,以及制备这些形式的方法,包括这些形式的药物组合物,以及这些形式在治疗中的应用。
  • TETRADENTATE LIGAND, AND PRODUCTION METHOD THEREFOR, SYNTHETIC INTERMEDIATE THEREOF, AND TRANSITION METAL COMPLEX THEREOF
    申请人:TAKASAGO INTERNATIONAL CORPORATION
    公开号:US20190127407A1
    公开(公告)日:2019-05-02
    The present invention relates to: a compound as a ligand in a variety of catalytic organic synthetic reactions; a method for producing the compound; a synthetic intermediate of the compound; and a transition metal complex which has the compound as a ligand. The compound includes a compound represented by the following general formula (1 A ):
    本发明涉及:一种化合物作为各种催化有机合成反应中的配体;制备该化合物的方法;该化合物的合成中间体;以及以该化合物作为配体的过渡属配合物。该化合物包括以下通用式(1A)所表示的化合物。
  • NOVEL SALT 628
    申请人:Briggner Lars-Erik
    公开号:US20100216843A1
    公开(公告)日:2010-08-26
    6-Methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 4-methylbenzenesulfonate and a novel crystalline form thereof are disclosed together with processes for preparing such salt and form, pharmaceutical compositions comprising such a salt and form, and the methods of treatment using such a salt and form.
    6-甲基-5-(1-甲基-1H-吡唑-5-基)-N-[5-(甲磺酰基)吡啶-2-基]甲基}-2-氧代-1-[3-(三甲基)苯基]-1,2-二氢吡啶-3-羧酰胺 4-甲基苯磺酸盐及其一种新的结晶形式,以及制备这种盐和形式的方法,包含这种盐和形式的药物组合物,以及使用这种盐和形式进行治疗的方法。
  • CHIRAL TETRADENTATE LIGAND, METHOD FOR PRODUCING SAME AND TRANSITION METAL COMPLEX OF SAID CHIRAL TETRADENTATE LIGAND
    申请人:TAKASAGO INTERNATIONAL CORPORATION
    公开号:US20200369700A1
    公开(公告)日:2020-11-26
    The present invention relates to a compound represented by the formula (1 A ). G represents a group selected from the group consisting of a monovalent group represented by the formula (G P ) and a monovalent group represented by the formula (G S ). R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 each independently represent a hydrogen atom or a group selected from the group consisting of an alkyl group, an alkenyl group, an aryl group, an aralkyl group, an alkoxy group, a halogeno group, and a halogeno alkyl group.
    本发明涉及一种由式(1A)表示的化合物。G代表从单价基团(GP)表示的基团和从单价基团(GS)表示的基团中选择的基团。R4、R5、R6、R7、R8、R9、R10、R11和R12各自独立地表示氢原子或从烷基、烯基、芳基、芳基烷基、烷氧基、卤素基和卤素烷基组成的基团中选择的基团。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫